Recently, Global Brands Magazine, headquartered in London, UK, announced its 2025 Global Brand Awards, with Yiling Pharmaceutical winning the “Excellence in Cardiovascular & Respiratory Care Innovation” award.
Official Award Website：Global Brand Award Winners 2025 – Global Brands Magazine
As one of the world’s leading brand rating agencies, Global Brands Magazine attracts approximately 8.4 million annual visitors. The selection process for its annual “Global Brand Awards” is extremely rigorous—each year, nearly 20,000 companies participate in the evaluation, and the winners are determined after multiple assessments by its internal research team and independent external institutions. Past winners include internationally renowned companies such as Microsoft, HSBC, Emirates Airline, and Mercedes-Benz. In the healthcare sector, top global institutions such as Singapore General Hospital, India’s Apollo Hospitals, South Korea’s Samsung Medical Center, and China’s West China Hospital have all received this honor. Being listed alongside these world-class brands fully demonstrates the significance of Yiling Pharmaceutical’s award this time.
Yiling Pharmaceutical’s achievement stems from its three decades of unwavering commitment to advancing the industrialization of traditional Chinese medicine through innovation in the Theory of Collateral Diseases. In the highly regarded field of cardiovascular health, Yiling Pharmaceutical has leveraged its unique “Theory-Clinical-New Drug-Industry-Education” five-in-one operational model to establish a systematic intervention system covering the entire cardiovascular continuum. Its representative products, including Tongxinluo Capsules, Shensong Yangxin Capsules, and Qili Qiangxin Capsules, cover three major areas: ischemic cardiovascular and cerebrovascular diseases, arrhythmia, and chronic heart failure. Relevant evidence-based medical research findings have been published in top-tier international medical journals such as the Journal of the American Medical Association and Nature Medicine.
In the respiratory health sector, Yiling Pharmaceutical’s innovative achievements are equally impressive. In response to respiratory infectious diseases, the company’s developed Lianhua Qingwen and Lianhua Qingke Tablets have become representative clinical medications, with Lianhua Qingwen playing a significant role in past public health events. In early 2025, the company’s independently developed Class 1.1 innovative traditional Chinese medicine, Qifang Bitong Pian, received marketing approval, offering a new treatment option for patients with persistent allergic rhinitis and further enriching its respiratory disease product portfolio. This demonstrates the company’s strong R&D capabilities in leveraging traditional wisdom to meet unmet clinical needs.
Furthermore, Yiling Pharmaceutical maintains a consistently high level of R&D investment, with its revenue proportion leading the industry. This sustained commitment to innovation has yielded fruitful results. The company currently holds 17 innovative patented traditional Chinese medicines, covering eight major disease areas, including cardiovascular and cerebrovascular diseases, respiratory diseases, oncology, and diabetes. Its products are marketed in over 50 countries and regions worldwide.
Receiving the “Excellence in Cardiovascular & Respiratory Care Innovation” award from Global Brands Magazine is another international endorsement of Yiling Pharmaceutical’s commitment to comprehensive innovation and its approach to interpreting the principles of traditional Chinese medicine through modern science. According to reports, Yiling Pharmaceutical has previously won one first-prize National Science and Technology Progress Award, four second-prize National Science and Technology Progress Awards, and one second-prize National Technology Invention Award. Its “Diagnosis and Treatment Methods of Collateral Disease in Traditional Chinese Medicine” has been inscribed on the National Intangible Cultural Heritage List. In terms of international brand building, Yiling Pharmaceutical has been recognized as a “Brand Innovation Pioneer Enterprise”, selected as an excellent case in the Annual Report on Chinese Enterprises’ Global Communication and Brand Building (2024), and its “Traditional Wisdom + Modern Technology” dual-drive model has attracted widespread attention.